TechTaffy

tech:

taffy

Atomwise enters into an evaluation agreement with Pfizer

By TechTaffy Desk

Atomwise has entered into an evaluation agreement with Pfizer, in which the drug giant will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer.

Atomwise will computationally analyze millions of diverse small molecules for each of Pfizer’s identified target proteins using its AI platform, to predict those that may bind with high affinity to the selected target proteins.

Pfizer will pay a technology access fee and additional success-based payments for each target protein of interest, the companies said in a statement.

[Image courtesy: Atomwise]

Just in

Series A

Tembo raises $14M

Cincinnati, Ohio-based Tembo, a Postgres managed service provider, has raised $14 million in a Series A funding round.
Around the web

Raspberry Pi is now a public company — TC

Raspberry Pi priced its IPO on the London Stock Exchange on Tuesday morning at £2.80 per share, valuing it at £542 million, or $690 million at today’s exchange rate, writes Romain Dillet. 
Fundings

AlphaSense raises $650M

AlphaSense, a market intelligence and search platform, has raised $650 million in funding, co-led by Viking Global Investors and BDT & MSD Partners.
Around the web

Elon Musk’s xAI raises $6B to take on OpenAI — VentureBeat

Confirming reports from April, the series B investment comes from the participation of multiple known venture capital firms and investors, including Valor Equity Partners, Vy Capital, Andreessen Horowitz (A16z), Sequoia Capital, Fidelity Management & Research Company, Prince Alwaleed Bin Talal and Kingdom Holding, writes Shubham Sharma. 
IT

Capgemini partners with DARPA to explore quantum computing for carbon capture

Capgemini Government Solutions has launched a new initiative with the Defense Advanced Research Projects Agency (DARPA) to investigate quantum computing's potential in carbon capture.